Cambium Bio Limited, a clinical-stage regenerative medicine company, announced it has successfully completed an A$3.0 million capital raising round.The capital raising, approved by capital shareholders, is composed of:A$1.5 million strategic investment from AventaCell Biomedical CorpA$0.25 million investment from Zheng Yang Biomedical TechnologyA$0.146 million from Cambium Bio … [Read more...] about Cambium Bio completes funding to help advance dry eye disease treatment
News
Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101
Galimedix Therapeutics Inc. announced today the initiation of dosing in its Phase 1 clinical trial evaluating oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of the orally administered therapy.The Phase 1 study aims to enroll up to 40 healthy … [Read more...] about Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101
Neurotech CCO Scott Hunter passes away
Scott Hunter, Chief Commercial Officer of Neurotech Pharmaceuticals Inc., passed away on December 3, 2024.Hunter joined Neurotech in January 2023. “The entire Neurotech family mourns this loss,” the company said in a statement. “On behalf of the Board of Directors, the management team, and employees, we extend our deepest sympathies to Scott’s family.”In the statement, … [Read more...] about Neurotech CCO Scott Hunter passes away
VivaVision Biotech reports positive Phase 2 trial results of VVN461 for postoperative inflammation treatment following cataract surgery
VivaVision Biotech has announced positive topline results from its U.S. Phase 2 clinical trial evaluating VVN461-CS-201, a potent nonsteroidal dual JAK1/TYK2 immunomodulator, for the treatment of postoperative inflammation following cataract surgery.The multicenter, randomized, double-masked, vehicle-controlled study enrolled 91 participants who underwent routine unilateral … [Read more...] about VivaVision Biotech reports positive Phase 2 trial results of VVN461 for postoperative inflammation treatment following cataract surgery
Risk factors for cataracts in patients with diabetes mellitus
A research team from Romania identified a higher risk of cataract development in patients with diabetes mellitus (DM) who have had the disease for an extended period and who have had poor glycemic control in conjunction with systemic comorbidities,1 according to first author Adriana Ivanescu. She is from the Department of Second Internal Medicine Diabetes, Nutrition, Metabolic … [Read more...] about Risk factors for cataracts in patients with diabetes mellitus
Empagliflozin and the Risk of Retinopathy in Type 2 Diabetes
This cohort study evaluates risk and progression of nonproliferative diabetic retinopathy in patients with type 2 diabetes with empagliflozin vs a dipeptidyl peptidase 4 inhibitor. … [Read more...] about Empagliflozin and the Risk of Retinopathy in Type 2 Diabetes
Diabetic Retinopathy—Another Possible Target for SGLT2 Inhibitors?
In this edition of JAMA Ophthalmology, Tesfaye et al report on an observational study that suggests that empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may slow progression of diabetic retinopathy. … [Read more...] about Diabetic Retinopathy—Another Possible Target for SGLT2 Inhibitors?
Error in Text and Table
In the Original Investigation titled “Sterile Intraocular Inflammation Associated With Faricimab,” published online October 10, 2024, there was an incorrect term used in the Introduction and no Snellen equivalent visual acuity provided in the Results and Table. In the Introduction, the word biospecific was corrected to bispecific; in the Results and Table, the Snellen … [Read more...] about Error in Text and Table
Discrimination Within the US Ophthalmology Workforce
This cross-sectional study describes the frequency, nature, and outcomes of discrimination in the workplace experienced by US ophthalmologists and trainees. … [Read more...] about Discrimination Within the US Ophthalmology Workforce
Bilateral improvement in age-related macular degeneration following unilateral Aflibercept injection
The "fellow-eye effect" in anti-vascular endothelial growth factor (anti-VEGF) therapy is a rare phenomenon, particularly with aflibercept. This case report documents the first instance of this effect in Pakis... … [Read more...] about Bilateral improvement in age-related macular degeneration following unilateral Aflibercept injection